C
Cordio Medical
Provides a solution for monitoring patients with chronic heart failure (CHF) using free-speech voice analysis in a smartphone app
About Cordio Medical
Cordio Medical is an Israeli-based medical technology company that has developed a non-invasive solution for monitoring congestive heart failure (CHF). The company's flagship product, the HearO, is a mobile application that utilizes proprietary speech-processing technology to detect changes in a patient's voice. These vocal alterations can indicate fluid accumulation in the lungs, a primary symptom of worsening heart failure, allowing for early medical intervention.
Read full description
The system is designed for ease of use, enabling patients to monitor their condition from home by speaking into their smartphone. The data is then analyzed in the cloud, and the results are transmitted to the patient's healthcare provider. This facilitates remote patient management, with the goal of improving patient outcomes and reducing the economic burden of CHF on healthcare systems by preventing hospitalizations.
Cordio Medical's business model is centered on providing a Software-as-a-Service (SaaS) platform to healthcare organizations, including hospitals, clinics, and home care agencies. The company targets the large and growing market for cardiovascular disease management, offering a tool that integrates into existing telehealth and remote monitoring frameworks.
At a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Or Yehuda, Israel
- Employees
- 31
- Open positions
- None listed
- Dealroom signal
- 74.5/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Analytics, Data Analytics, Cardiology and cardiovascular, Respiratory, Pulmonary, Non-Invasive medical devices and treatments, Tech for Medical Professionals, Tech for Patients, Hard Tech
- Business model
- SaaS
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Cordio Medical.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jun 2022 | $18M | $72M | Peregrine Ventures · Ceros Financial Services | ↗ |
| EARLY VC✓Equity / VC | Jan 2022 | $3M | $12M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Cordio Medical is 1.2K monthly website visits, up 46.3% over the last three months. Cordio Medical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Peregrine Ventures
Series B and later1 investor entered at this stage
- CSCeros Financial Services
Other known investors2 additional known investors
G4A
OurCrowd
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cordio Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cordio Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.